recombinant soluble human hbegf (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
93
Structured Review
R&D Systems
recombinant soluble human hbegf
Recombinant Soluble Human Hbegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 84 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+soluble+human+hbegf/pmc05388552-66-0-25?v=R%26D+Systems
Average 93 stars, based on 84 article reviews
Recombinant Soluble Human Hbegf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 84 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+soluble+human+hbegf/pmc05388552-66-0-25?v=R%26D+Systems
Average 93 stars, based on 84 article reviews
recombinant soluble human hbegf - by Bioz Stars,
2026-07
93/100 stars
Images
1) Product Images from "Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation"
Article Title: Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation
Journal: The FASEB Journal
doi: 10.1096/fj.201600828R
Figure Legend Snippet: Affymetrix probe list
Techniques Used:
Figure Legend Snippet: HBEGF is decreased in patients with NB and correlates with survival. A) HBEGF expression in the microarray meta-dataset in benign neuroblastic tumors (ganglioneuroma/ganglioneuroblastoma) or NB tumors. ****P < 0.0001 (Mann-Whitney U test). B) Immunofluorescence in neuroblastoma specimens for HBEGF (green). DAPI nuclear stain in blue. Original magnification, ×40. Scale bar, 50 μM. C) HBEGF expression in patients with NB by stage. P < 0.0001, Kruskal-Wallis test. **P < 0.01, ***P < 0.001, ****P < 0.0001 Mann-Whitney U test for intergroup comparisons. D) Event-free survival (EFS) in patients with NB with low (bottom 50%; red) and high (top 50%; blue) HBEGF expression in the GSE49710 dataset. E) HBEGF expression in the GSE49710 dataset in nonamplified (NA) or MYCN-amplified (Amp) NB tumors. ****P < 0.0001 (Mann-Whitney U test). Box plots are presented as median (horizontal bars) and interquartile range (boxes).
Techniques Used: Expressing, Microarray, MANN-WHITNEY, Immunofluorescence, Staining, Amplification
Figure Legend Snippet: HBEGF promotes neuroblast differentiation in NB cells. A) Western blot for differentiation markers after 72 h of HBEGF treatment in BE2 and SK-N-AS. Densitometry for NF160 normalized to β-actin is shown as the percentage of control. B) Quantification of NF160 densitometry normalized to β-actin from 3 independent Western blots (5Y, BE2) or 8 independent Western blots (SK-N-AS) after 72-h treatment with 1 ng/ml HBEGF and presented as means ± sem. P < 0.001 (1-way ANOVA). *P < 0.05, **P < 0.01, ****P < 0.0001, 1-sample Student’s t test. C) Representative phase-contrast images of BE2 cells after 72 h of treatment with HBEGF. Arrows identify long neurites. Original magnification, ×10. Scale bar, 100 μM. D) Quantification of neurite length using NeuronJ after 72 h of treatment with HBEGF from 3 independent experiments. P < 0.01 (1-way ANOVA). *P < 0.05, 1-sample Student’s t test. E) Western blot for differentiation markers after 72 h of HBEGF (0.5 or 1 ng/ml), FGF2 (1 or 10 ng/ml), or ATRA (1 or 10 μM). Densitometry for NF160 normalized to β-actin is shown as the percentage of control. F) Western blot for differentiation markers after 72 h HBEGF (0, 0.25, 0.5, 0.75, 1, 2 ng/ml) and a neutralizing HBEGF antibody (nAb; 0.0075, 0.015, 0.03, 0.05, 0.1, or 0.5 μg/ml). Densitometry for NF160 normalized to β-actin is shown as the percentage of control. G) Western blot for β3-tubulin and HBEGF in SHEP stably expressing an NTC shRNA or shRNA to HBEGF (shHBEGF #1, #2). Densitometry for β3-tubulin normalized to β-actin is shown as the percentage of control. H) Linear regression analyses using the microarray meta-dataset (left) or the GSE49710 dataset (right).
Techniques Used: Western Blot, Control, Stable Transfection, Expressing, shRNA, Microarray
Figure Legend Snippet: Schwannian stroma-derived HBEGF promotes neuroblast differentiation. A) Immunofluorescence in NB specimens using HBEGF (green) and S100 schwannian stroma (red) antibodies. DAPI nuclear stain in blue. Original magnification, ×40. Scale bar, 50 μM. B) Western blot for differentiation markers in 5Y after 72 h of coculture or treatment with conditioned medium from SHEP stably expressing an NTC shRNA construct or shRNA to HBEGF (shHBEGF #1, #2). Densitometry for NF160 normalized to β-actin is shown as the percentage of control.
Techniques Used: Derivative Assay, Immunofluorescence, Staining, Western Blot, Stable Transfection, Expressing, shRNA, Construct, Control
Figure Legend Snippet: HSPGs and EGFR interact to promote HBEGF-mediated neuroblast differentiation. A) Western blots for differentiation markers after 72-h treatment with 10 ng/ml soluble (s)TβRIII or sCD44 or 100 ng/ml sGPC1, sGPC3, or sSDC3 in the absence or presence of 0.5 ng/ml HBEGF in 5Y cells. B) Densitometry for NF160 normalized to β-actin is shown as the percentage of control, a dosecourse of HBEGF in SK-N-AS after 96-h TβRIII knockdown. C) Densitometry for NF160 normalized to β-actin is shown as the percentage of control, 0.5 μg/ml heparin, ODSH, 2-O desulfated heparin (2DES), 6-O desulfated heparin (6DES), or N desulfated heparin (NDES) in the absence or presence of 0.5 ng/ml HBEGF in SK-N-AS. D) Densitometry for NF160 normalized to β-actin is shown as the percentage of control, EGFR inhibitors for 72 h followed by 48 h of 1 ng/ml HBEGF treatment. Densitometry for NF160 normalized to β-actin is shown as the percentage of control. E) In situ proximity ligation assay in SK-N-AS after 5 min of treatment with 1 ng/ml HBEGF or 1 ng/ml EGF. Original magnification, ×40. Scale bars, 50 μM. Normalized TβRIII/EGFR complexes per cell (75–100 cells/condition) from 6 independent experiments. P < 0.001 (1-way ANOVA). *P < 0.05, ****P < 0.0001, 1-sample Student’s t test. F) Analysis of event-free survival in the GSE49710 dataset stratified by the top and bottom 50% for HBEGF, then TGFBR3, then EGFR expression (left) and analysis of event-free survival stratified by the top and bottom 12.5% for HBEGF, then TGFBR3, then EGFR expression (middle) compared with stratification by MYCN amplification status (right). NA, nonamplified.
Techniques Used: Western Blot, Control, Knockdown, In Situ, Proximity Ligation Assay, Expressing, Amplification
Figure Legend Snippet: HBEGF induces neuroblast differentiation via ERK and STAT3 signaling and up-regulation of ID1. A) Western blot in SK-N-AS for phosphorylated and total STAT3 or ERK1/2 after 72 h treatment with 1 ng/ml HBEGF. Densitometry for phosphorylated STAT3 or phosphorylated ERK1/2 normalized to β-actin is shown as the percentage of control. B) Western blot for ID1 in BE2 and SK-N-AS after 72 h treatment with a dosecourse of HBEGF. Densitometry for ID1 normalized to β-actin is shown as the percentage of control. C) Western blot for ID1 in SHEP stably expressing an NTC shRNA or shRNA to HBEGF (shHBEGF #1, #2). Densitometry for ID1 normalized to β-actin is shown as the percentage of control. D) Western blot in SK-N-AS after 96 h ID1 knockdown and 72 h HBEGF treatment. Densitometry for NF160 normalized to β-actin is shown as the percentage of control. E) Linear regression analyses using the microarray meta-dataset (left) or the GSE49710 dataset (right). F) Western blot for differentiation markers and ID1 after 24 h cotreatment with 1 ng/ml HBEGF and the indicated doses of U0126 or CI-1040. Densitometry for NF160 normalized to β-actin is shown as the percentage of control. G) Western blot for differentiation markers after 72 h expression of an empty-vector control (EV) or a dominant negative STAT3 (DN STAT3) construct and 48 h treatment with 1 ng/ml HBEGF or 48 h treatment with ruxolitinib and 24 h treatment with 1 ng/ml HBEGF. Densitometry for NF160 normalized to β-actin is shown as the percentage of control.
Techniques Used: Western Blot, Control, Stable Transfection, Expressing, shRNA, Knockdown, Microarray, Plasmid Preparation, Dominant Negative Mutation, Construct
Figure Legend Snippet: HBEGF suppresses neuroblast proliferation. A) Proliferation index from 3 (5Y) or 4 (SK-N-AS, BE2) replicates (means ± sem) of thymidine incorporation after HBEGF treatment for 24 h (SK-N-AS), 48 h (5Y), or 72 h (BE2), normalized to untreated control. P < 0.0001 (1-way ANOVA). **P < 0.01, ***P < 0.001 (1-sample Student’s t test). B) Western blot for p21 after 72 h of HBEGF treatment in BE2 and SK-N-AS. Densitometry for p21 normalized to β-actin is shown as the percentage of control. C) Linear regression analyses using the microarray meta-dataset (left) or the GSE49710 dataset (right). D) SK-N-AS NTC and SK-N-AS shHBEGF#1 subcutaneous xenograft. Tumors were measured at d 19 using calipers, and this measurement was used to calculate the fold change in tumor growth after 21, 24, 26, and 31 d. **P < 0.01, Kruskal-Wallis to compare curves.
Techniques Used: Control, Western Blot, Microarray